HIV Infections Clinical Trial
Official title:
Increasing Identification of Patients With Primary HIV Infection (PHI) Through a Questionnaire Intervention in an Emergency Department (ED) Setting
The purpose of this study is to identify patients who have early HIV infection. Patients who
have been infected with HIV recently may develop flu-like symptoms within 3 to 8 weeks.
Those who go to the hospital emergency room for these symptoms and who may have been exposed
to HIV recently will be given a questionnaire and the opportunity to be tested for HIV.
Most people develop flu-like symptoms shortly after becoming infected with HIV, and many of
these people go to a hospital emergency room for treatment. However, most doctors do not
think of testing people with flu-like symptoms for HIV. This study will look at a plan to
change this because it is very important to identify patients who have early HIV infection.
Viral load (level of HIV in the blood) is very high during early HIV infection, and it is
easy to spread HIV to others during this period. Patients who learn they are HIV-positive
can stop risky behavior that might spread HIV to other people. Also, patients who find out
early that they are HIV positive are able to begin anti-HIV treatment sooner, slowing the
disease.
Early identification of HIV infection is an important factor in preventing the spread of
HIV. It is hoped that patients who learn their HIV status will decrease behavior that may
lead to further transmission of HIV. Infectiousness of HIV is high during PHI, with some of
the highest viral loads seen shortly after infection. Treatment for HIV infection now
typically begins after identification of infection, but treatment during PHI may positively
affect the long-term outcome of the disease. The majority of patients present with flu-like
symptoms during PHI. Many seek medical attention, often in an ED setting, but rarely is the
diagnosis of HIV considered. Specific screening efforts, therefore, are needed to identify
infected individuals before standard ELISA testing would detect infection. This study
attempts to demonstrate that administration of a questionnaire to a targeted population
presenting symptomatically with viral syndrome in an inner city ED will result in increased
screening for HIV and identification of patients with PHI.
Patients presenting to the UCSD ED with viral syndromes are approached by staff and asked to
complete a questionnaire regarding possible recent HIV exposure. Patients with risk for
recent HIV infection are offered participation in this study. Pre-test counseling includes a
review of: (1) the risk of discrimination if the test is positive, (2) the implications of a
positive test upon the health of the patient and that of their sexual or needle-use
partners, and (3) the possibility that this test, like any laboratory test, could be wrong.
Consenting patients have blood drawn for HIV RNA testing and for possible HIV p24 antigen
confirmatory test. Blood is labeled with a unique identifying number and not by name. When
results become available, patients go the UCSD Treatment Center to learn the results and for
post-test counseling.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |